VolitionRX Stock (AMEX:VNRX), Analyst Ratings, Price Targets, Predictions

The latest price target for VolitionRX (AMEX: VNRX) was reported by Cantor Fitzgerald on March 27, 2024. The analyst firm set a price target for $2.50 expecting VNRX to rise to within 12 months (a possible 201.57% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for VolitionRX (AMEX: VNRX) was provided by Cantor Fitzgerald, and VolitionRX reiterated their overweight rating.

There is no last upgrade for VolitionRX.

The last downgrade for VolitionRX Ltd happened on February 1, 2023 when Benchmark changed their price target from N/A to N/A for VolitionRX Ltd.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of VolitionRX, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for VolitionRX was filed on March 27, 2024 so you should expect the next rating to be made available sometime around March 27, 2025.

While ratings are subjective and will change, the latest VolitionRX (VNRX) rating was a reiterated with a price target of $0.00 to $2.50. The current price VolitionRX (VNRX) is trading at is $0.83, which is within the analyst’s predicted range.